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A new class of two-dimensional (2D) nanomaterial, transition metal dichalcogenides (TMDCs) such as MoS2, MoSe2,
WS2, and WSe2 which have fantastic physical and chemical properties, has drawn tremendous attention in different
fields recently. Herein, we for the first time take advantage of the great potential of MoS2 with well-engineered
surface as a novel type of 2D nanocarriers for gene delivery and therapy of cancer. In our system, positively charged
MoS2-PEG-PEI is synthesized with lipoic acid-modified polyethylene glycol (LA-PEG) and branched polyethylenimine
(PEI). The amino end of positively charged nanomaterials can bind to the negatively charged small interfering RNA
(siRNA). After detection of physical and chemical characteristics of the nanomaterial, cell toxicity was evaluated by
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Polo-like kinase 1 (PLK1) was investigated
as a well-known oncogene, which was a critical regulator of cell cycle transmission at multiple levels. Through
knockdown of PLK1 with siRNA carried by novel nanovector, qPCR and Western blot were used to measure the
interfering efficiency; apoptosis assay was used to detect the transfection effect of PLK1. All results showed that the
novel nanocarrier revealed good biocompatibility, reduced cytotoxicity, as well as high gene-carrying ability without
serum interference, thus would have great potential for gene delivery and therapy.
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RNA interference (RNAi) is a newly discovered cellular
strategy for silencing genes in a sequence-specific manner
[1-3]. At present, small interfering RNA (siRNA)-mediated
gene regulation or therapy has shown immense potential
in treating various diseases by silencing abnormally up-
regulated genes [4-6]. In this kind of gene therapy, siRNA
could be delivered into cells utilizing either viral vectors
or non-viral carriers, causing degradation of targeted
mRNA and subsequently leading to the silence of specific
protein expression [7]. The success of gene therapy is
largely dependent on the development of a safe and effi-
cient gene delivery system [8-10]. Viral vectors have been* Correspondence: xfxue@suda.edu.cn; caowei_728@163.com;
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in any medium, provided the original work is pprimarily used in gene therapy due to their high delivery
efficiency [11,12]. However, despite of the advantages such
as simplicity of use, ease of large-scale production, and
lack of specific immune response [13,14], viral vectors
might bring the side effects such as endogenous virus re-
combination, oncogenic effects, and unexpected immune
response [15] while non-viral vectors could circumvent.
Many non-viral-based gene delivery vectors, such as
cationic polymers [16], silica nanoparticles [17], iron
oxide nanoparticles [18], and many other types [19-21],
have been extensively explored in recent years. Though
they are widely used for research in gene delivery, their
toxicity and low in vivo efficiency limited their further
application [22].
Thus, seeking for new biological materials has become
an important research direction [23]. In recent years,
nanoparticles have demonstrated unique physical and
biological properties that can be applied to overcome
the issues in gene and drug delivery systems due to itsOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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size is usually 10 to 100 nm, which is capable of pene-
trating through the submucosal layers and enhances the
efficiency in gene transfection level [25]. Besides, a num-
ber of cationic polymers have been investigated as gene
carriers, such as polyethylenimine (PEI) due to its spe-
cific features. PEI has high pH-buffering capacity, lower
cytotoxicity, and high transfection efficiency [26], thus
has tremendous potential in gene therapy.
The novel nanomaterials, which could be developed
from graphene or transition metal dichalcogenides
(TMDCs) such as MoS2, MoSe2, WS2, and WSe2,
came to be new emerging non-viral gene delivery car-
riers [27-30]. Graphene and its analog, TMDCs, which
are the two-dimensional (2D) sp2-bonded nanocarbon
with excellent electronic, optical, and mechanical properties
have been extensively studied in the past decades [31,32].
In this study, MoS2 was formulated as nanoparticles
and modified by PEI on the particles to increase the sur-
face charge, providing as a promising gene carrier candi-
date. The obtained positively charged MoS2-PEG-PEI
could be loaded with siRNA for gene delivery. Our re-
sults for the first time suggested TMDCs as a novel type
of 2D nanovector in gene delivery with low cytotoxicity
and high transfection efficiency without serum interfer-




Branched polyethylenimine (PEI) with molecular weight
(MW) of 25 kDa and 3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium bromide (MTT) were obtained from
Sigma-Aldrich (St. Louis, MO, USA). Lipoic acid-modified
polyethylene glycol (LA-PEG) polymers were purchased
from PegBio (Suzhou, China). Lipofectamine 2000 trans-
fection kit, 4′,6′-diamidino-2-phenylindole (DAPI), and
fetal bovine serum (FBS) were obtained from Invitrogen
(Carlsbad, CA, USA). Dulbecco’s modified Eagle’s
medium (DMEM) was purchased from Thermo Scien-
tific (Waltham, MA, USA). SiRNA-targeting polo-like
kinase 1 (PLK1) gene and negative control siRNA with
a scrambled sequence were synthesized with fluores-
cent label by GenePharma Co., LTD (Suzhou, China).
Sequence was as follows: siPLK1, 5′-AUAUUCGA
CUUUGGUUGCCdTdT-3′, siN.C., 5′-ACGUGACAC
GUUCGGAGAAdTdT-3′. The entire antibodies were
supplied by Abcam Co., LTD (Cambridge, MA, USA).
Synthesis of single-layer MoS2 nanosheets
MoS2 nanosheets were synthesized by the Morrison
method [33]. Shortly, 500 μg MoS2 crystal was soaked
in 500 μL of 1.6 M n-butyllithium solution in hexane
for 2 days inside a nitrogen glove box. Following theintercalation by lithium, the MoS2 sample was filtered
and washed repeatedly with 80 mL hexane to remove
excess lithium and other organic residues. Intercalated
MoS2 sample was then removed immediately from glove
box and ultrasonicated in water for 1 h to allow effective
exfoliation, obtaining exfoliated MoS2 which was then
centrifuged in 3,000 rpm to remove unexfoliated MoS2
and excess LiOH in the precipitates. The supernatant
was dialyzed against deionized water using membranes
with molecular weight cut-off (MWCO) of 14 kDa for
2 days to remove lithium compounds and other residue
ions, obtaining MoS2 nanosheets dispersed in water for
future use.PEGylation of MoS2 nanosheets and preparation of
MoS2-PEG-PEI
Ten milligrams of lipoic acid-modified PEG (LA-PEG)
was added into 1 mg of MoS2 nanosheets dispersed in
2 mL of water. After sonication for 20 min and stirring
overnight, excess PEG polymers were removed by centri-
fugal filtration with 100 kDa MWCO filters (Millipore,
Billerica, MA, USA) and several times of water washing.
The obtained MoS2-PEG or MoS2-PEG-FA were highly
water-soluble and stored less than 4°C for use.
Generally, PEI used during this experiment was pre-
dissolved in deionized water. One milligram of PEGy-
lated MoS2 nanosheets and 0.1 mL PEI (50 mg/mL)
were mixed in 2 mL deionized water. The mixture was
stirred overnight under room temperature. Free PEI was
removed by hyperfiltration.Characterization of the prepared nanomaterials
Atomic force microscopy (AFM) (Veeco Inc., Plainview,
NY, USA) was used to characterize the size and thick-
ness of MoS2 nanosheets before and after PEG coating.
Elemental analysis data were acquired by an elemental
analyzer (EA1110 CHNO-S, Carlo Erba, Cornaredo, MI,
Italy). Zeta potentials and size distributions of nanoparti-
cles were measured by a Nano-ZS90 nanoparticle analyzer
(Malvern Instruments Ltd.).Loading of siRNA onto MoS2-PEG-PEI and agarose gel
electrophoresis assay
From elemental analysis (nitrogen content), we estimated
that the PEI content in MoS2-PEG-PEI conjugate was
about 32%. MoS2-PEG-PEI was mixed with 20 pmol
siRNA in 20 μL deionized water at different nitrogen/
phosphor (N/P) ratios (N/P =0, 5, 10, 15, 20). The mix-
tures were then incubated for 1 h at room temperature be-
fore they were analyzed by 1% agarose gel electrophoresis
in Tris-acetate-EDTA (TAE) buffer.
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HepG2 cell line obtained from American Type Culture
Collection (ATCC, Manassas, VA, USA) was cultured in
Dulbecco’s modified Eagle’s medium (DMEM) contain-
ing 10% FBS and 1% penicillin/streptomycin at 37°C in a
humidified 5% CO2-containing atmosphere.
For siRNA transfection, HepG2 cells were seeded in
35 mm culture dishes at a density of 1 × 105 cells per
well. We diluted 200 pmol FAM-siRNA in 200 μL
serum-containing DMEM and various concentrations of
MoS2-PEG-PEI in 200-μL serum-containing DMEM.
The two solutions were mixed together and incubated
for 20 min at room temperature before being added into
cells, maintaining the final volume at 2 mL. Here, we
used Lipofectamine 2000 as the positive transfection
agent and siRNA with a scrambled sequence as the
negative control. After 6 h of transfection, cells were
washed twice with PBS (pH = 7.4) and then imaged by a
laser scanning confocal microscope (Leica SP5, Leica
Microsystems, Wetzlar, Germany). The cell nuclei could
be stained by DAPI. After 6 h siPLK1 without FAM label
transfection following the same protocol, we transfered
the cells into new fresh complete media and incubated
at 37°C for additional 48 h. Cells could be stained with
the calcein-AM/propidium iodide (PI) to determine the
viability.
RNA extraction and quantitative real-time PCR (qPCR)
All transfected cells were washed twice with PBS and
the total RNA was extracted using the TRIzol reagent
(Takara, Dalian, China) according to the manufacturer’s
protocol. Then, RNA was subsequently reversely tran-
scribed to complementary DNA (cDNA) using M-MLV
First-Strand cDNA Synthesis Kit (Invitrogen, Carlsbad,
CA, USA). Afterwards, qPCR analysis was performed
using Platinum SYBR Green qPCR SuperMix-UDG kits
(Invitrogen, Carlsbad, CA, USA) on an ABI Prism 7500
Real-Time PCR system (Applied Biosystems, Foster City,
CA, USA).The relative amount of PLK1 normalized to
β-actin was calculated according to the 2−ΔΔCt method.
Each sample was run in triplicate. The primer sequences
were as follows: 5′-AGCCTGAGGCCCGATACTACC
TAC-3′ (PLK1-forward), 5′-ATTAGGAGTCCCACACA




Total proteins were prepared by standard procedures
and quantified by the Bradford BSA Protein Assay Kit.
Equivalent amounts of protein were resolved and mixed
with loading buffer, then loaded on 10% SDS-PAGE gel
and subsequently electrotransferred to a polyvinylidene
difluoride (PVDF) membrane, which was blocked for 2 hat room temperature with 5% non-fat dry milk in PBS.
After blocking, the membrane was incubated with
mouse anti-human PLK1 antibody at 1:1,000 at 4°C
overnight followed by incubation with goat-anti-mouse
IgG antibody at 1:2,000 for 1 h at room temperature.
Mouse-anti-human β-actin antibody diluted at 1:1,000
was used as a control. Densitometric values of protein
bands were quantified using Image Analysis software on
Evolve-512 photometric system.
Flow cytometry analysis
Flow cytometry analysis was employed to quantify the
cell apoptosis post treatment by using Annexin V-FITC/
PI apoptosis detection kit. In details, 24 h after transfec-
tion, cells were detached by trypsin, washed with PBS,
and then re-suspended in 500 μL Annexin V binding
buffer containing 1 μg/L Annexin V-FITC and 4 μg/L
PI. The samples were then analyzed by flow cytometry
(BD FACS Calibur, BD Biosciences, San Jose, CA, USA).
Statistical analysis
Statistical analysis was performed using SPSS15.0 software.
Data are expressed as the mean ± standard deviation from
at least three separate experiments. Differences between
groups were analyzed using Student’s t-test. A value of
p <0.05 was considered statistically significant.
Results and discussion
The schematic illustration to show the construction of
MoS2-PEG-PEI/siRNA is shown in Figure 1a. Two-
dimensional MoS2 nanosheets were prepared by the
chemical exfoliation method according to the literature
[34]. To enhance the stability of MoS2 in serum, the as-
made single-layer MoS2 nanosheets were then conju-
gated the lipoic acid-modified PEG (LA-PEG) which is
well-known for its excellent ability to prevent non-
specific binding of proteins on nanomaterial surface
together with the branched polyethylenimine (PEI)
polymer. From elemental analysis (nitrogen content),
we estimated that the PEI content in MoS2-PEG-PEI
conjugate was about 32%. According to the previous
studies [28,34,35], we used the thiol chemistry method
to functionalize MoS2 nanosheets by coating the sur-
face of MoS2 with LA-PEG which contained a disul-
fide group on the PEG terminal. Furthermore, the
obtained positively charged MoS2-PEG-PEI could be
loaded with siRNA which was negatively charged for gene
delivery. To improve the physiological stability and bio-
compatibility of MoS2 nanosheets, surface modification of
the 2D nanosheets was required before using them for
bioapplications. MoS2-PEG-PEI showed excellent stability
in both saline and serum-containing cell medium at room
temperature (Additional file 1: Figure S1a). Consistent to
this observation, MoS2-PEG-PEI kept their consistent
Figure 1 Synthesis and characterization of MoS2 and MoS2-PEG. (a) A scheme showing the preparation of MoS2-PEG-PEI and the
subsequent loading with siRNA. (b) AFM images of MoS2 before and after PEGylation. (c, d) AFM measured diameter (c) and thickness (d)
distributions of MoS2 and MoS2-PEG. Over 100 nanosheets were counted for each sample.
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containing cell medium (Additional file 1: Figure S1b).
The great stability of MoS2-PEG-PEI in the presence of
serum makes it a promising candidate for gene delivery
without serum interference.
AFM was used to characterize MoS2 nanosheets be-
fore and after PEGylation (Figure 1b). It revealed that
the original chemically-exfoliated MoS2 nanosheets
showed an average diameter of ∼ 100 nm and an aver-
age thickness of ∼ 1.8 nm. After the LA-PEG coating,
the average diameter of MoS2 nanosheets decreased
to ∼ 50 nm because ultrasonication step might partially
break down those nanosheets. However, the average
thickness of PEGylated MoS2 increased to ∼ 2.8 nm,
owing to the existence of PEGylation (Figure 1c). Thesize distributions of MoS2 before and after PEG coating
are suggested by AFM images and dynamic light scatter-
ing (DLS) data in the meantime (Figures 1c and 2a).
We then evaluated the size distributions and zeta poten-
tials of different layers of MoS2-PEG-PEI (Figure 2a,b). The
zeta potentials of MoS2 and MoS2-PEG were measured to
be −17.9 and −8.9 mV, respectively. MoS2-PEG-PEI with
positively charged PEI coating showed an increased zeta
potential of 19.9 mV. DLS data revealed that MoS2-PEG
had much smaller sizes compared to original MoS2 nano-
sheets. And the size of MoS2-PEG-PEI was between MoS2
and MoS2-PEG.
Before we used the MoS2 nanosheets in in vitro drug
delivery experiments, we tested their potential toxicity
by the MTT assay which was performed to determine
Figure 2 Characterization of different layers of MoS2 nanosheets. (a) Hydrodynamic sizes of MoS2, PEGylated MoS2, and MoS2-PEG-PEI.
(b) Zeta potentials of MoS2 nanosheets before and after two layers of polymer coatings measured in water.
Kou et al. Nanoscale Research Letters 2014, 9:587 Page 5 of 9
http://www.nanoscalereslett.com/content/9/1/587the relative cell viability. HepG2, HeLa, and 293 T cells
were respectively incubated with various concentrations
of MoS2, MoS2-PEG, and MoS2-PEG-PEI for 24 h.
In general, we found that there was no significant
cytotoxicity about MoS2, PEGylated MoS2, and MoS2-
PEG-PEI (Figure 3a-c). Three kinds of cells survived
after 24 h incubation even under the high concentration
of MoS2 up to 0.2 mg/mL. Cells which were incubated
with MoS2-PEG showed higher viability compared to
those which were incubated with plain MoS2. However,Figure 3 In vitro cell toxicity assay of different layers of MoS2 nanosh
determined by the MTT assay after incubation with various concentrations
DHE-positive cells (cells with significant oxidative stress) after incubation w
24 h. H2O2 (200 μM) incubated cells were used as the control. Error bars wMoS2-PEG-PEI exhibited slightly reduced viability mainly
because it was positively charged.
The above result obviously displayed that the cytotox-
icity of MoS2 nanosheets, like many other nanomaterials,
was closely related to their surface chemistry. Therefore,
well-designed surface modification plays an important
role in the biomedical application of this type of 2D
nanomaterials.
Previous studies revealed that many nanoparticles could
generate reactive oxygen species (ROS) such as •O2−, •OH,eets. Relative viabilities of HepG2 (a), HeLa (b), and 293 T (c) cells
of MoS2, MoS2-PEG, and MoS2-PEG-PEI for 24 h. (d) Percentages of
ith various concentrations of MoS2, MoS2-PEG, and MoS2-PEG-PEI for
ere based on four parallel samples.
Figure 4 Cell uptake and in vitro siRNA transfection. (a) Confocal microscopy images of HepG2 cells after incubation with MoS2–PEG–PEI/
FAM-siRNA for 4 h. The fluorescence from DAPI (blue colored) and FAM-siRNA fluorescence (green colored) showed well co-localization inside
cells. (b) Western blotting results to determine PLK1 expression of HepG2 cells after various treatments indicated. β-Actin was also detected as
the internal control. (c) Quantitative determination of PLK1 expression for different samples based on Western blotting data from (b). (d) The
expression levels of PLK1 mRNA determined by qPCR. PLK1 mRNA levels were expressed as a relative index normalized against β-actin. Error bars
were based on triplicated samples. P values were calculated by the Student’s t-test: ∗, #p <0.05 (n =3).
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tive stress to harm biomolecules of cells like proteins and
DNA [36]. Thus, in order to further test the low toxicity of
MoS2, PEGylated MoS2, and MoS2-PEG-PEI, intracellular
ROS levels were assessed using a dihydroethidine (DHE)
probe. In accord with the MTT result, no notable increase
in the percentage of DHE-positive cells was observed for
cells treated with MoS2, PEGylated MoS2, or MoS2-PEG-
PEI for 24 h, suggesting minimal oxidative stress inducedby those nanosheets (Figure 3d). Low toxicity of MoS2
nanosheets is ensured to further explore the nanomaterials
as a drug carrier.
Polo-like kinase 1 (PLK1) was reported to be crucial in
DNA replication [37,38]. And it was always overex-
pressed in many types of cancer cells [39]. The silencing
of PLK1 would trigger cell apoptosis. Herein, we would
like to use our MoS2-PEG-PEI as a nanovector for the
delivery of PLK1 siRNA in order to test the transfection
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nanoparticles, we mixed MoS2-PEG-PEI with siRNA at
different N/P ratios and carried out an agarose gel elec-
trophoresis (AGE) assay (Additional file 2: Figure S2).
Concluded from the AGE result, when MoS2-PEG-PEI
was mixed with siRNA at N/P ratio above 5, significant
retardation of siRNA movement in gel electrophoresis
was observed. In contrast, bare siRNA could not be
retarded.
We next used confocal fluorescence microscope to
study the cellular uptake of MoS2-PEG-PEI/siRNA com-
plex (Figure 4a). The fluorescent signal from DAPI and
FAM-labeled siRNA were simultaneously detected. Clear
co-localization of signals from two different channels
was detected, suggesting that siRNA was successfully
shuttled into cells by MoS2 nanosheets.Figure 5 In vitro RNAi-induced cancer therapy. (a) Flow cytometry anal
micrographs showing the calcein-AM (green, for living cells) and PI (red, fo
in (a) is based on triplicated samples. P values were calculated by the StudTo determine the expression of PLK1 after MoS2-in-
duced siRNA transfection, qPCR and Western blotting
was conducted (Figure 4b,c). The qPCR result showed
that lipofectamine-mediated transfection of siPLK1
(Figure 4b,c) led to a notable decrease of PLK1 com-
pared to the control group (siN.C.). For cells treated
with MoS2-PEG-PEI/siPLK1, obviously decreased PLK1
expression was observed with the increase of N/P ratio.
In consistence with the qPCR result, Semi-quantification
data of Western blotting (Figure 4d) uncovered that the
PLK1 silencing efficiency with MoS2-PEG-PEI/siPLK1
was achieved as well as that with Lipofectamine 2000 at
N/P ratio of 20, which indicated MoS2 as an effective
transfection carrier.
It was documented that PLK1, as an oncogene, would
trigger cell apoptosis when downregulated in cancer cellsysis data of HepG2 cells after being treated. (b) Fluorescence
r dead cells) double-stained HepG2 cells. Scale bar: 100 μm. Error bars
ent’s t-test: ∗p <0.05 (n =3).
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MoS2 and the role of siPLK1 transfection, flow cytome-
try analysis was employed to quantify the cell apoptosis
post treatment (Figure 5a). The results showed that an
increasing proportion of apoptotic cells treated with
MoS2-PEG-PEI/siPLK1 were detected with the increase
of N/P ratio. Microscopy images of calcein-AM and PI
double-stained (living and dead cells) HepG2 cells also
showed an increasing proportion of apoptotic cells treated
with MoS2-PEG-PEI/siPLK1, which had a good accord-
ance with the flow cytometry result (Figure 5b). These re-
sults further confirmed that MoS2-PEG-PEI acted as a
kind of perfect nanocarrier for gene delivery.
The success of gene therapy mostly relies on the devel-
opment of the gene delivery vector [41]. Currently, gene
delivery systems are mainly categorized into viral and
non-viral groups. In terms of the viral system, target
genes can be packed into a virus like adenovirus, which
has the capacity to inject its DNA into the host cells.
However, the side effects of viral carriers, such as re-
combinant viral vectors reverting to their original wild
type or the possibility of adverse immune responses to
the host, limited their further application [42,43]. In
contrast, non-viral vectors should circumvent some of
the problems occurring with the viral vectors. Moreover,
non-viral vectors have advantages in simplicity of use,
ease of large-scale production [44].
In our present study, we utilized the MoS2-based ma-
terial as gene carrier. Notably, the current results exhib-
ited TMDCs as a novel type of 2D nanovector in gene
delivery with low cytotoxicity and high transfection effi-
ciency, promising for future applications in non-viral
based gene therapy. Compared with many other widely
explored agents, MoS2 was an essential trace element of
life. Besides, our 2D MoS2-PEG-PEI nanosheets suggest
no obvious cytotoxicity. However, although preliminary
in vitro experiments suggest no obvious cytotoxicity of
MoS2-PEG nanosheets, we should still keep in mind that
the factors controlling the pharmacokinetics and biodis-
tribution of non-viral vectors were complicated in vivo.
More deep studies were required to understand the po-
tential toxicity as well as possible metabolism of this
type of TMDC material in vivo. Thus, more attention
and effort should be taken to make the perfect gene car-
rier suitable for clinical use.
Conclusions
Our work opened a novel and exciting avenue in gene
delivery system. Combined with the advantages of high
transfection efficiency of PEI, a new MoS2-based gene
vector was successfully developed for gene therapy of
cancer.
For the first time, MoS2 nanosheets with appropriate
surface modification of PEG and PEI could be employedas a novel class of 2D nanocarriers for efficient siRNA
delivery. And it was found that the MoS2-PEG-PEI
nanosheets exhibited no observable toxicity to cells at
the tested concentrations. Utilizing such a nanocarrier
for PLK1 silencing, we achieved optimal gene knock-
down and cancer cell apoptosis with N/P ratio of 20.
Therefore, our study demonstrated that MoS2 with a
well designed and engineered surface could serve as a
nanocarrier that offered the novel opportunities in bio-
medical therapy [45].
Additional files
Additional file 1: Figure S1. MoS2-PEG-PEI stability. (a) MoS2-PEG-PEI
stability in water, saline, and serum-containing cell medium at room
temperature. (b) MoS2-PEG-PEI kept their consistent hydrodynamic sizes
at about 50 nm in the serum-containing cell medium.
Additional file 2: Figure S2. Gel retardation assay. Agarose gel
electrophoresis of bare siRNA, MoS2 nanosheets, and mixtures of
MoS2-PEG-PEI and siRNA at different N/P ratios. Each sample was
incubated at room temperature for 20 min before electrophoresis.
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